EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies

Manar A Al Hindawi, Nourhan E Omran, Mohamed H Mostafa, Aya M Alshihabi, Mohammed I El-Gamal, Hany A Omar

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2026.178679 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Manar A Al Hindawi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of S…. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Drug Resistance, Neoplasm, Mutation. Die Arbeit nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In metastatic melanoma with a BRAFV600 mutation, inhibitors of BRAF and MEK have improved survival. Resistance may be acquired through late genetic alterations that restore mitogen-activated protein kinase (MAPK) signaling. Resistance can also be adaptive, involving early and reversible transcriptional or metabolic shifts that generate drug-tolerant cells, or intrinsic, arising from pre-existing conditions such as phosphatase and tensin homolog (PTEN) loss or an AXL receptor tyrosine kinase-high (AXL-high) state. For instance, some tumors exhibit phenotypic plasticity, dynamically switching between AXL-high invasive and microphthalmia-associated transcription factor-high (MITF-high) proliferative cell states, leading to relapse after an initial response. When compared to upfront targeted therapy, first-line immune checkpoint blockades typically confer greater long-term survival, according to major clinical trials examining therapeutic sequencing (DREAMseq, SECOMBIT, EBIN). BRAF and MEK inhibitors remain effective when used as second-line therapy, and high-risk patients can safely achieve quick tumor control without sacrificing results by receiving a brief course of targeted therapy prior to immunotherapy. To enable precision-guided adaptive dosage, (ctDNA) has emerged as a valuable biomarker for early detection of resistance mutations and real-time monitoring of disease dynamics. The article concludes that new investigational approaches to overcoming resistance include triplet regimens (targeted therapy plus immunotherapy), co-targeting alternative pathways (such as AXL receptor tyrosine kinase-high (AXL) or phosphoinositide 3-kinase-AKT (PI3K-AKT)), and incorporating radiotherapy to eradicate resistant clones. However, strategies such as intermittent (adaptive) dosing have failed to improve outcomes in clinical trials. Ongoing trials and advances in artificial intelligence-driven personalization may further refine treatment selection and improve long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafDrug Resistance, NeoplasmMutationMolecular Targeted TherapyBiomarkers, TumorProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimals

Stichwörter der Autor:innen

BRAF-Mutant melanomaCirculating tumor DNAImmune checkpoint blockadeMAPK pathway inhibitionPhenotypic plasticityResistance mechanisms

Substanzen

Proto-Oncogene Proteins B-rafBiomarkers, TumorProtein Kinase InhibitorsBRAF protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates. Electronic address: hany…

Zitieren

APA

Al Hindawi, M. A., Omran, N. E., Mostafa, M. H., Alshihabi, A. M., El-Gamal, M. I., & Omar, H. A. (2026). Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178679

Vancouver

Al Hindawi MA, Omran NE, Mostafa MH, Alshihabi AM, El-Gamal MI, Omar HA. Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178679

BibTeX
@article{AlHindawi2026,
  author = {Al Hindawi, Manar A and Omran, Nourhan E and Mostafa, Mohamed H and Alshihabi, Aya M and El-Gamal, Mohammed I and Omar, Hany A},
  title = {Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2026.178679}
}
Kostenlos starten →